Stock info Espirite | Filter  Basic-Info

Espirite

The past year was a good investment year for Espirite investors

The stock lost over the past 12 months at around 48 percent. Over the past 5 years the stock lost a massive -66,62 percent. Espirite's revenues between 2011 and 2015 were far from constant and moved between 36,84 million euros and 27,51 million euros. Espirite's net incomes between 2011 and 2015 were very volatile and moved between 2,31 million euros and -7,2 million euros.

Espirite is active in the pharmaceutical sector. The global pharmaceutical companies gained around 75 percent over the last 10 years. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-2016) there is a minus of 75 percent.

The Dutch company paid out dividends in the past 5 years. Espirite's dividend return over the period 2011 - 2015 was around 0,15 percent per year.

Espirite financed with relatively low debt

At the end of 2015 the pharmaceutical company's balance sheet equaled 48,13 million euros. At the end of 2015 the total debt positon equaled 32,88 million euros. This is around 68,31 percent of the total balance sheet. At the end of 2015 the pharmaceutical company's stock was traded with a price/earnings-ratio -2. So the stock' value was -2 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the Dutch stock can be seen as a value stock.

At the end of 2015 the Dutch company's market capitalization equaled around 23,67 million euros. At the end of 2015 around 10,03 million stocks were listed.

All Espirite's financial reports are located here. More information about Espirite can be found it's website. .